Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 39 member 7 (SLC39A7), commonly known as ZIP7, is a transmembrane zinc transporter primarily localized to the endoplasmic reticulum (ER) and Golgi apparatus membranes. It plays a critical role in maintaining cellular zinc homeostasis by facilitating the transport of zinc ions from these intracellular storage compartments into the cytosol. Cytosolic zinc release mediated by SLC39A7 acts as a signaling second messenger, activating downstream pathways such as AKT, mTOR, and MAPK that promote cell proliferation, growth, and survival.\n\nConsequently, SLC39A7 is frequently upregulated and hyperactivated in various malignancies, including breast, gastric, and colorectal cancers, where it contributes to tumor progression, metastasis, and endocrine therapy resistance. Additionally, SLC39A7 is essential for B-cell development, glycemic control in skeletal muscle, and protection against ER stress. Pharmacological targeting of SLC39A7 is an emerging therapeutic strategy, with small-molecule inhibitors like NVS-ZP7-4 and NVS-ZP7-7 being utilized to disrupt zinc homeostasis, induce ER stress, and selectively trigger apoptosis in cancer cells.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 39 member 7 (SLC39A7).